MOTS-c Levels and Sarcopenia Risk in Chronic Peritoneal Dialysis Patients: A Pilot Study
Authors:
- Mariateresa ZicarelliMZMariateresa Zicarelli
- Marta GrecoMarta Greco
- Stefanos RoumeliotisStefanos Roumeliotis
- Maria Elisa Lo VascoMVMaria Elisa Lo Vasco
- Francesco DragoneFDFrancesco Dragone
- Christodoula KourtidouCKChristodoula Kourtidou
- Ioannis AlekosIAIoannis Alekos
- Roberta MisitiRMRoberta Misiti
- Daniela Patrizia FotiDaniela Patrizia Foti
- Giuseppe CoppolinoGiuseppe Coppolino
- Vassilios LiakopoulosVassilios Liakopoulos
- Evangelia DounousiEDEvangelia Dounousi
Open Access
Abstract
Background and Objectives: Sarcopenia is exceedingly frequent in end-stage kidney disease (ESKD) patients on dialysis, including those undergoing peritoneal dialysis (PD), and is of multifactorial origin. MOTS-c is a mitochondrial-derived peptide that promotes muscle growth whose levels are unbalanced in ESKD. In this study, we evaluated MOTS-c balance and its relationship with sarcopenia risk in an ESKD-PD cohort. Materials and Methods: MOTS-c was measured in serum, urine, and dialysate samples of 32 chronic PD patients. Patients were thus screened for sarcopenia risk by the SARC-F tool, anthropometric measurements, and physical performance tests. Results: PD patients with a very high sarcopenia risk (SARC-F ≥ 2) had significantly lower serum (sMOTS-c) and higher dialysate (dMOTS-c) levels, suggesting an increased peritoneal clearance of this substance (d/s MOTS-c). sMOTS-c levels were directly correlated with muscle performance in physical tests, while an opposite relationship was found with dMOTS-c and d/sMOTS-c. ROC analyses demonstrated the diagnostic potential of MOTS-c, particularly in combination with physical and anthropometric assessments, to identify PD patients at very high risk of sarcopenia. Conclusions: Chronic PD may negatively affect MOTS-c balance, which, in turn, may contribute to enhanced sarcopenia risk. Larger studies are needed to confirm these observations and to validate the potential utility of this substance as a biomarker for improving sarcopenia risk stratification in PD patients.Keywords
This publication has 25 references indexed in Scilit:
- Prevalence of sarcopenia in patients with chronic kidney disease: a global systematic review and meta‐analysisJournal of Cachexia, Sarcopenia and Muscle, 2024
- Optimising the use of SARC-F for the identification of muscle weakness by considering alternative cut-points: findings from the Newcastle SarcScreen projectEuropean Geriatric Medicine, 2023
- Screening, diagnosis and monitoring of sarcopenia: When to use which tool?Clinical Nutrition ESPEN, 2022
- Diagnosis, prevalence, and mortality of sarcopenia in dialysis patients: a systematic review and meta‐analysisJournal of Cachexia, Sarcopenia and Muscle, 2022
- Reliability and Concurrent Validity of the SARC-F and Its Modified Versions: A Systematic Review and Meta-AnalysisJournal of the American Medical Directors Association, 2021
- Ability of SARC-F to Find Probable Sarcopenia Cases in Older AdultsThe Journal of nutrition, health and aging, 2021
- SARC-F Questionnaire Detects Frailty in Older AdultsThe Journal of nutrition, health and aging, 2020
- Sarcopenia in chronic kidney disease: what have we learned so far?Journal Of Nephrology, 2020
- SARC-F as a Screening Tool for Sarcopenia and Possible Sarcopenia Proposed by AWGS 2019 in Hospitalized Older AdultsThe Journal of nutrition, health and aging, 2020
- MOTS-c: A novel mitochondrial-derived peptide regulating muscle and fat metabolismFree Radical Biology and Medicine, 2016